Ivosidenib (Tibsovo)

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells.

Diseases for which it is used

• IDH1-mutated AML

History of changes in FDA indication

• 7/20/2018: Granted FDA approval "for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test."

Also known as

• Code name: AG-120
• Brand name: Tibsovo